Treatment of drug-resistant TB
Resistance to TB drugs is a formidable obstacle to effective TB care and prevention globally. Multidrug-resistant TB (MDR-TB) is multifactorial and fuelled by improper treatment of patients, poor management of supply and quality of drugs, and airborne transmission of bacteria in public places. Case management becomes difficult and the challenge is compounded by catastrophic economic and social costs that patients incur while seeking help and on treatment.
News, events and announcements
Tuberculosis (TB) strains with multidrug- and rifampicin-resistance (MDR/RR-TB) are more difficult to treat than drug-susceptible TB and threaten global progress towards the targets of the End TB Strategy set by the World Health Organization (WHO). The WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update addresses the mandate of WHO to inform health professionals in Member States on how to improve MDR/RR-TB care.
In 2018, WHO convened a Guideline Development Group (GDG) to update its policy recommendations on the treatment of MDR/RR-TB. The GDG was composed of a multidisciplinary group of external experts with experience in different aspects of the programmatic management of MDR/RR-TB as well as affected individuals. Ahead of their meeting in July 2018 in Switzerland, the GDG defined seven priority questions for the updated guidelines to cover. Topical areas of uncertainty on the composition and duration of longer MDR-TB regimens for adults and children, on when the standardized 9-12 month shorter MDR-TB regimen may be offered and the use of culture to monitor treatment response were included in the scope. Other aspects of MDR/RR-TB care for which no new evidence has emerged since the last time WHO policy was revised, such as the timing of antiretroviral therapy in MDR/RR-TB patients with human immunodeficiency virus (PLHIV), use of surgery and different models of care, were not reviewed and previous policies thus remain valid.
Rapid diagnostic test and shorter, cheaper treatment signal new hope for multidrug-resistant tuberculosis patients
New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.
Updates on situation of drug-resistant TB in Papua New Guinea, with special emphasis on Daru Island
This document provides an update on the progress made since May 2015 and WHO's position to further support the country's efforts
WHO is currently updating this guidance and convened a meeting of the Guideline Development Group in Geneva, Switzerland from 12 to 13 November 2015